SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Eur J Cancer. 1976; 12: 419424.
  • 2
    Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst. 1991; 83: 491-496.
  • 3
    Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985; 2: 282.
  • 4
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Engl J Med. 1989; 320: 479484.
  • 5
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 6
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998; 352: 98101.
  • 7
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998; 352: 9397.
  • 8
    Cuzick J, Forbes J, Edwards R, et al.; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet. 2002; 360: 817824.
  • 9
    Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361: 296300.
  • 10
    Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95: 526532.
  • 11
    Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999; 91: 18291846.
  • 12
    Gail MH, Brinton LA, Byar DO, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 18791886.
  • 13
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early onset breast cancer. Implications for risk prediction. Cancer. 1994; 73: 643651.
  • 14
    Port ER, Montgomery LL, Heert AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001; 8: 580585.
  • 15
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM. Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2002; 94: 1504.
  • 16
    Vogel VC, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer. 2002; 3: 153159.
  • 17
    Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev Med. 1995; 24: 412419.
  • 18
    Hatcher MB, Fallowfield L, A'Hern R. The psychological impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ. 2001; 322: 76.
  • 19
    Nakhlis F, Hou N, Acharya S, et al. Impact of the breast cancer prevention trial (BCPT) on tamoxifen (tam) utilization in patients with T1a/b N0 breast cancer [abstract 96]. Proc Am Soc Clin Oncol. 2003; 22: 24.
  • 20
    Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000; 92: 12171227.
  • 21
    Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001; 93: 16241632.
  • 22
    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312: 146151.
  • 23
    Morrow M. Pre-cancerous breast lesions: implications for breast cancer prevention trials. Int J Radiat Oncol Biol Phys. 1992; 23: 10711078.
  • 24
    Hoogerbrugge N, Bult P, DeWidt-Leveret LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol. 2003; 21: 4145.
  • 25
    U.S. Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002; 137: 5658.
  • 26
    Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999; 17: 19291955.
  • 27
    Kinsinger LS, Harris R, Woolf SH, Sox HS, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence. Ann Intern Med. 2002; 137: 5969.